DCP
REGN icon

Distillate Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Distillate Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.1M Buy
28,570
+192
+0.7% +$147K 1.16% 20
2025
Q4 		$21.9M Sell
28,378
-8,734
-24% -$5.93M 1.13% 24
2025
Q3 		$20.9M Buy
37,112
+9,129
+33% +$5.16M 1.08% 26
2025
Q2 		$14.7M Sell
27,983
-3,481
-11% -$1.94M 0.79% 62
2025
Q1 		$20M Sell
31,464
-677
-2% -$466K 1.02% 30
2024
Q4 		$22.9M Buy
+32,141
New +$27M 1.13% 24
2023
Q2 		– Sell
-15
Closed -$12.3K – 39
2023
Q1 		$12.3K Buy
15
+1
+7% +$754 3.16% 13
2022
Q4 		$10.1K Buy
+14
New +$10.3K 0.93% 70
2022
Q3 		– Sell
-12,485
Closed -$7.38M – 120
2022
Q2 		$7.38M Buy
+12,485
New +$8.12M 1.05% 26
2022
Q1 		– Sell
-8,956
Closed -$5.66M – 124
2021
Q4 		$5.66M Buy
8,956
+2,056
+30% +$1.26M 0.95% 31
2021
Q3 		$4.17M Sell
6,900
-19
-0.3% -$11.8K 1.11% 22
2021
Q2 		$3.87M Buy
6,919
+1,265
+22% +$641K 1.08% 23
2021
Q1 		$2.67M Buy
5,654
+2,510
+80% +$1.22M 0.87% 47
2020
Q4 		$1.5M Buy
+3,144
New +$1.7M 0.72% 79

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Distillate Capital Partners's REGN Position: Q1 2026 in Review

Distillate Capital Partners increased its Regeneron Pharmaceuticals (REGN) stake by 0.68% in Q1 2026, buying an estimated $147K and bringing the position to 28,570 shares worth $22.1M. The position accounts for 1.16% of the portfolio, ranked #20.

Distillate Capital Partners first reported a position in REGN in Q4 2020 and has held it in 14 quarters since. The position peaked at $22.9M in Q4 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Distillate Capital Partners held 28,570 shares of Regeneron Pharmaceuticals worth $22.1M as of Q1 2026.
  • Distillate Capital Partners bought 192 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $147K.
  • Regeneron Pharmaceuticals made up 1.16% of Distillate Capital Partners's portfolio in Q1 2026, its #20 holding.
  • Distillate Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
  • Distillate Capital Partners's Regeneron Pharmaceuticals position peaked at $22.9M in Q4 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Distillate Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.